CA4P, a water-soluble prodrug of CA4, is used as a vascular-disrupting agent for the treatment of ovarian, glioma, non-small cell lung cancer (NSCLC), pancreatic neuroendocrine tumors, and etc. (Grisham et al., 2018). The gene discussed is CA4; the disease is central nervous system cancer.